Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi TherapeuticsPRNewsWire • 03/09/23
Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/23/23
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period ActivityBusiness Wire • 02/23/23
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 02/21/23
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/02/23
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial ResultsBusiness Wire • 02/02/23
Alnylam Pharmaceuticals Starts 2023 With In-Line Revenue And A Full Slate Of Clinical Read-OutsSeeking Alpha • 01/10/23
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional UpdatesBusiness Wire • 01/08/23
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/03/23
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 DiabetesBusiness Wire • 12/21/22
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D DayBusiness Wire • 12/15/22
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 12/08/22